Feedback (LSE:FDBK), the AIM-quoted clinical software company behind the Bleepa platform, published final results on 6 November 2026 that showed a narrower operating loss and a lower cash balance at the year end. The directors noted that the company's plans depend on securing new contracts or additional funding, and that the cash position would support activity until the end of the first quarter of 2027 without new contracts.

Company Overview

Feedback develops digital health technology for the NHS. Its main product, Bleepa, is a clinical communication and care pathway platform that lets clinicians share information, including medical images, and manage patients along defined pathways.

The company has been working on care pathways that move patients away from traditional outpatient appointments. In an update in July 2026, it said 100% of breathlessness patients on a Sussex pathway had been diverted from outpatient appointments, and that an insomnia pathway had been rolled out across Kent, Surrey and Sussex. These examples show how LSE:FDBK applies its platform to specific clinical areas.

Care pathways describe the sequence of steps a patient follows from referral through assessment and treatment. By managing information and communication along those steps, a platform such as Bleepa is designed to help clinicians coordinate care and to reduce the need for some outpatient visits.

Latest Developments

In a Business update on 29 October 2026, Feedback said a contract extension with Queen Victoria Hospital, worth £127,000, would run until March 2027. It also said the Surrey and Sussex integrated care board had provided an extra £249,000 to fund further development of Bleepa. The company added that it was exploring a multi-year elective care transformation opportunity with a large integrated care board. This could begin with a paid pilot, followed by wider commissioning from April 2027.

Earlier in the year, Feedback said it was pursuing a national contract opportunity with NHS England, with a decision expected by the end of 2026. It also reported technical progress, including a new version of Bleepa and integrations with the NHS e-Referral Service, Patients Know Best and an electronic medical record system.

Integrations are significant for a clinical platform because they allow information to move between the systems clinicians already use, which can make a new tool easier to adopt within a hospital or integrated care board.

Integrated care boards plan and fund health services for the populations in their areas, so contracts with them can influence a number of NHS providers at once. The additional £249,000 from the Surrey and Sussex board is directed at developing Bleepa further, which signals continuing local support for the platform.

Financial Picture

For the year to 31 May 2026, Revenue was £0.78m, down from £0.89m, while total sales were £0.94m, with Bleepa accounting for 91%. Gross Margin was 79%, compared with 88% a year earlier. The operating loss before interest and tax narrowed to £3.24m from £4.21m, and the EBITDA loss was £2.99m, compared with £3.06m. The loss per share was 7.96p, and the results included an Impairment of intangible assets of £0.31m.

Cash at 31 May 2026 was £2.73m, compared with £5.95m a year earlier. Feedback does not pay a dividend, which is consistent with a company that is investing in product development and building its customer base.

Total sales of £0.94m include Bleepa, which accounted for 91%, so the platform is the main product of the business. The impairment of intangible assets of £0.31m is a non-cash accounting item and is shown separately in the results.

Sector and index Context

Feedback is one of several small digital health companies in the FTSE AIM All Share Index seeking to win business from the NHS. The NHS has been looking for ways to reduce waiting lists and manage elective demand, which creates opportunities for pathway technology. Bleepa's focus on moving patients along defined pathways is aimed at this challenge, which is one reason the company has concentrated on elective care in its recent announcements.

NHS procurement can take time, and decisions often depend on central or regional budgets, so the timing of revenue can be difficult to predict for smaller suppliers such as LSE:FDBK.

A national contract with NHS England, if awarded, would operate on a larger scale than the local and regional agreements that make up much of the company's current activity, which is why the decision expected by the end of 2026 is followed closely.

Factors to Monitor

Contract timing and funding are the main considerations. The narrowing of the operating loss from £4.21m to £3.24m shows progress on costs, while the outcome of the larger commissioning decisions will determine the pace of revenue growth. The business works with a small number of NHS customers, so each contract extension and new commissioning decision is relevant.

What to Watch Next

The key milestones are the NHS England national contract decision, which the company expected by the end of 2026, and progress on the elective transformation opportunity with a large integrated care board. Market Participants will also watch for any funding announcement from LSE:FDBK and the outcome of the Annual General Meeting notified alongside the final results.